Meridigen Biotech
Taipei, Taiwan· Est.
Taiwanese MSC‑focused biotech developing neuro‑vascular and pulmonary cell therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese MSC‑focused biotech developing neuro‑vascular and pulmonary cell therapies.
NeurologyPulmonologyRegenerative Medicine
Technology Platform
Proprietary hUC‑MSC isolation, expansion, and GMP‑compliant CMC platform enabling large‑scale, consistent manufacturing and detailed potency profiling.
Opportunities
Advancing a pre‑clinical MSC candidate into Phase I could unlock licensing deals and establish Meridigen as a regional leader in neuro‑vascular and pulmonary cell therapies.
Risk Factors
Heavy reliance on MSC technology faces regulatory uncertainty, scale‑up challenges, and competition from larger cell‑therapy firms.
Competitive Landscape
Competes with Asian MSC developers such as WuXi AppTec and Cellmax, differentiating through a dual service‑drug model and a focus on neuro‑vascular and lung indications.